<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20051209/bs_nm/merck_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051209/2005_12_09t083755_317x450_us_vioxx_journal.jpg?x=9 1&amp;y=130&amp;sig=PpmO27i_akUmCY.kR16rkg--" align="left" height="130" width="91" alt="A bottle of prescription arthritis and pain medication Vioxx is seen on a shelf at a New York City Pharmacy in this file photo taken on September 30, 2004. A prestigious medical journal on Thursday said Merck and Co. withheld information about the dangers of arthritis drug Vioxx in a key study, an alleged lapse that analysts said could hurt Merck as it defends itself against Vioxx-related lawsuits. (Mike Segar/Files/Reuters)" border="0" /></a>Reuters - As the first federal jury deliberates
whether Merck &amp; Co.'s painkiller Vioxx contributed to a
Florida man's death, investors on Friday digested new claims
that the battered company withheld key data about the drug's
dangers.</p><br clear=all>

View the entire article: Merck jury deliberates amid new claims (Reuters)